Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nifekalant vs Amiodarone for Postoperative AF
NCT05169866Phase 3Recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- May 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nifekalant in Atrial fibrillation (AFib) (2 arms), sponsored by Beijing An Zhen Hospital. Primary endpoint: Rate of cardioversion to sinus rhythm at 4 hours. Started May 2022; status: recruiting.
02
Drugs
nifekalant
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT05169866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05169866.